|
1
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic, and
end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun S, Schiller JH, Spinola M and Minna
JD: New molecularly targeted therapies for lung cancer. J Clin
Invest. 117:2740–2750. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ciancio N, Galasso MG, Campisi R, Bivona
L, Migliore M and Di Maria GU: Prognostic value of p53 and Ki67
expression in fiberoptic bronchial biopsies of patients with non
small cell lung cancer. Multidiscip Respir Med. 7:292012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moorhead GB, Trinkle-Mulcahy L and
Ulke-Lemée A: Emerging roles of nuclear protein phosphatases. Nat
Rev Mol Cell Biol. 8:234–244. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fiscella K, Franks P and Shields CG:
Perceived family criticism and primary care utilization:
Psychosocial and biomedical pathways. Fam Process. 36:25–41. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu X, Nguyen TA, Moon SH, Darlington Y,
Sommer M and Donehower LA: The type 2C phosphatase Wip1: An
oncogenic regulator of tumor suppressor and DNA damage response
pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gorgoulis VG, Vassiliou LV, Karakaidos P,
Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr,
Kastrinakis NG, Levy B, et al: Activation of the DNA damage
checkpoint and genomic instability in human precancerous lesions.
Nature. 434:907–913. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Castellino RC, De Bortoli M, Lu X, Moon
SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA and Kim JY:
Medulloblastomas overexpress the p53-inactivating oncogene
WIP1/PPM1D. J Neurooncol. 86:245–256. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saito-Ohara F, Imoto I, Inoue J, Hosoi H,
Nakagawara A, Sugimoto T and Inazawa J: PPM1D is a potential target
for 17q gain in neuroblastoma. Cancer Res. 63:1876–1883.
2003.PubMed/NCBI
|
|
12
|
Hirasawa A, Saito-Ohara F, Inoue J, Aoki
D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I:
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas
with poor prognosis and identification of PPM1D and APPBP2 as
likely amplification targets. Clin Cancer Res. 9:1995–2004.
2003.PubMed/NCBI
|
|
13
|
Hu W, Feng Z, Modica I, Klimstra DS, Song
L, Allen PJ, Brennan MF, Levine AJ and Tang LH: Gene amplifications
in well-differentiated pancreatic neuroendocrine tumors inactivate
the p53 pathway. Genes Cancer. 1:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Yang Y, Peng Y, Austin RJ, van
Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey
T, et al: Oncogenic properties of PPM1D located within a breast
cancer amplification epicenter at 17q23. Nat Genet. 31:133–134.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Satoh N, Maniwa Y, Bermudez VP, Nishimura
K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J and
Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker
for lung adenocarcinoma patient survival. Cancer Sci.
102:1101–1106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Travis WD, Brambilla E, Müller-Hermelink
HK and Harris CC: Tumours of the lung. World Health Organization
Classification of Tumours. Pathology and Genetics of Tumours of the
Lung, Pleura, Thymus and Heart. IARC Press. (Lyon). 102004.
|
|
17
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park JY, Song JY, Kim HM, Han HS, Seol HS,
Jang SJ and Choi J: p53-Independent expression of wild-type
p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated
cancer cell lines and human tumors. Int J Biochem Cell Biol.
44:896–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bulavin DV, Demidov ON, Saito S,
Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G,
Nebreda AR, Anderson CW, et al: Amplification of PPM1D in human
tumors abrogates p53 tumor-suppressor activity. Nat Genet.
31:210–215. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nannenga B, Lu X, Dumble M, Van Maanen M,
Nguyen TA, Sutton R, Kumar TR and Donehower LA: Augmented cancer
resistance and DNA damage response phenotypes in PPM1D null mice.
Mol Carcinog. 45:594–604. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Demidov ON, Kek C, Shreeram S, Timofeev O,
Fornace AJ, Appella E and Bulavin DV: The role of the MKK6/p38 MAPK
pathway in Wip1-dependent regulation of ErbB2-driven mammary gland
tumorigenesis. Oncogene. 26:2502–2506. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao JX, ZW, Sun L, Luo HH and Gu Y:
Expression of Wip1 in non small cell lung cancer tissue and cells.
Chin J Pathophysiol. 25:1731–1735. 2009.(In Chinese).
|
|
23
|
Singhal S, Vachani A, Antin-Ozerkis D,
Kaiser LR and Albelda SM: Prognostic implications of cell cycle,
apoptosis, and angiogenesis biomarkers in non-small cell lung
cancer: A review. Clin Cancer Res. 11:3974–3986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirasawa A, Aoki D, Inoue J, Imoto I,
Susumu N, Sugano K, Nozawa S and Inazawa J: Unfavorable prognostic
factors associated with high frequency of microsatellite
instability and comparative genomic hybridization analysis in
endometrial cancer. Clin Cancer Res. 9:5675–5682. 2003.PubMed/NCBI
|
|
25
|
Liang C, Guo E, Lu S, Wang S, Kang C,
Chang L, Liu L, Zhang G, Wu Z, Zhao Z, et al: Over-expression of
wild-type p53-induced phosphatase 1 confers poor prognosis of
patients with gliomas. Brain Res. 1444:65–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Campling BG and El-Deiry WS: Clinical
implication of p53 mutation in lung cancer. Mol Biotechnol.
24:141–156. 2003. View Article : Google Scholar : PubMed/NCBI
|
